|1.||Gareri, Pietro: 3 articles (09/2005 - 01/2004)|
|2.||Condorelli, Daniele: 3 articles (09/2005 - 01/2004)|
|3.||Belluardo, Natale: 3 articles (09/2005 - 01/2004)|
|4.||De Sarro, Giovambattista: 3 articles (09/2005 - 01/2004)|
|5.||Walker, Brian R: 3 articles (03/2005 - 01/2003)|
|6.||Stewart, P M: 3 articles (07/2003 - 02/2000)|
|7.||Thakur, Poonam: 2 articles (02/2015 - 04/2014)|
|8.||Nehru, Bimla: 2 articles (02/2015 - 04/2014)|
|9.||Hanani, Menachem: 2 articles (01/2015 - 07/2007)|
|10.||Bagirici, Faruk: 2 articles (01/2015 - 01/2012)|
|1.||Duodenal Ulcer (Curling's Ulcer)
01/01/1978 - "The result is highly significant (P less than 0.016) and confirms the therapeutic efficacy of carbenoxolone sodium positioned-release capsules in the treatment of duodenal ulcers. "
01/01/1976 - "Carbenoxolone sodium has been shown to accelerate the rate of healing of both gastric and duodenal ulcers, but its overall value in duodenal ulcer is probably less because of the high rate of natural remission of duodenal ulcers. "
01/13/1979 - "These results confirm the therapeutic efficacy of carbenoxolone sodium in duodenal ulcer. "
01/01/1981 - "A double-blind randomized trial was performed in order to evaluate the efficacy of carbenoxolone (Biogastron duodenal) in reducing recurrences of duodenal ulcer. "
01/13/1979 - "In a double-masked trial, 43 patients with an endoscopically confirmed, symptomatic duodenal ulcer were allocated at random to treatment with either carbenoxolone sodium or placebo, both provided in identical "positioned-release" capsules. "
01/01/1977 - "Complete ulcer healing occurred in a significantly greater number of patients receiving Duogastrone than placebo, the significance being greater after four and eight weeks treatment (P less than 0-01) than at 12 weeks (P less than 0-02). "
04/01/1978 - "Carbenoxolone may exert its metabolic effects systemically, but its ulcer-healing effects topically; additional studies are needed to test this hypothesis."
02/01/2001 - "The anticonvulsant potential of gap-junction blockers such as carbenoxolone, now in clinical use for treatment of ulcer disease, should be considered."
01/01/1998 - "In particular, 38b and 39b showed a potent anti-ulcer activity, 3- to 25-fold higher than carbenoxolone. "
06/01/1990 - "Its anti-ulcer activities were similar to those of carbenoxolone. "
12/01/2004 - "In particular, intravenous or intraperitoneal administration of carbenoxolone (5-30 mg/kg) produced a dose-dependent and significant reduction in the clonic and tonic phases of the audiogenic seizures in GEPRs. "
03/01/2012 - "Tales of a dirty drug: carbenoxolone, gap junctions, and seizures."
01/01/2012 - "Total spike number and the generalized seizure duration were reduced in the carbenoxolone treated group compared to the PTZ group. "
01/19/2004 - "Systemic administration of carbenoxolone (1-40 mg/kg, intraperitoneally (i.p.)) was able to produce a dose-dependent decrease in DBA/2 audiogenic seizure severity score. "
04/29/2003 - "It can be concluded that carbenoxolone possesses anticonvulsant, muscle relaxant and hypnotic effects, which could contribute to the control of petit mal and grand mal seizures."
|4.||Stomach Ulcer (Gastric Ulcer)
04/01/1967 - "Side effects of carbenoxolone sodium: a study of ambulant therapy of gastric ulcer."
01/01/1987 - "Thirty-four patients with gastric ulcer were treated with the new Bulgarian preparation pharmaxolon-Pharmachim, for 20 days under clinical conditions. "
01/01/1981 - "Carbenoxolone effectively reduced the gastric ulcer formation by cold-restraint stress when it was administered i.p. "
01/01/1980 - "Between 1970 and 1979, 140 patients aged between 19 and 84 years with endoscopically confirmed gastric ulcer (GU), were treated with Biogastrone in reducing doses for 6 months. "
01/01/1980 - "Long-term therapy with carbenoxolone in the prevention of recurrence of gastric ulcer. "
12/25/2015 - "Further study is warranted to clarify the effects of carbenoxolone on hypothalamic regulation of energy balance in obesity. "
01/01/2012 - "Here, we tested the effect of 11β-HSD inhibitor, carbenoxolone (CBX) on obesity and associated comorbidities in obese rats of WNIN/Ob strain, a new animal model for genetic obesity. "
12/25/2015 - "In conclusion, the results of this study show that carbenoxolone has protective effects against tunicamycin induced-ER stress and apoptosis in hypothalamic neurons, suggesting its direct protective effects against obesity. "
03/01/2005 - "We examined the regeneration of cortisol in vivo in obesity, and the effects of the 11HSD1 inhibitor carbenoxolone. "
04/01/2008 - "We have examined the metabolic effects of daily administration of carbenoxolone (CBX), a naturally occurring 11beta-hydroxysteroid dehydrogenase (11beta-HSD1) inhibitor, in mice with high fat diet-induced insulin resistance and obesity. "
|5.||Heptanol (1 Heptanol)
|6.||Glutamic Acid (Glutamate)
|1.||Bed Rest (Bedrest)
|2.||Drug Therapy (Chemotherapy)